Hematopoietic and lymphoid cell neoplasm
MONDO:0044881A neoplasm arising from hematopoietic cells found in the bone marrow, peripheral blood, lymph nodes and spleen (organs of the hematopoietic system). Hematopoietic cell neoplasms can also involve other anatomic sites (e.g. central nervous system, gastrointestinal tract), either by metastasis, direct tumor infiltration, or neoplastic transformation of extranodal lymphoid tissues. The commonest forms are the various types of leukemia, Hodgkin and non-Hodgkin lymphomas, myeloproliferative neoplasms, and myelodysplastic syndromes.
Also known as: HEMOLYMPHORETICULAR tumor, malignant, haematological neoplasm, haematological tumour, haematopoietic and lymphoid neoplasms, haematopoietic cancer, haematopoietic cell tumour, haematopoietic malignancy, NOS, haematopoietic neoplasm
7339 clinical trials for this condition and its sub-types, 486 tagged with Hematopoietic and lymphoid cell neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hematopoietic and lymphoid cell neoplasm
-
Lymphoid neoplasm 11 trials · 4,272 incl. sub-types
6 sub-types
- Lymphoma 609 trials · 4,252 incl. sub-types Sub-types →
- Lymphoid leukemia 24 trials · 1,362 incl. sub-types Sub-types →
- Precursor lymphoblastic lymphoma/leukemia 12 trials · 1,344 incl. sub-types Sub-types →
- Neoplasm of immature B and T cells 0 trials · 1,319 incl. sub-types Sub-types →
- T-cell and NK-cell neoplasm 8 trials · 324 incl. sub-types Sub-types →
- Malignant lymphatic vessel tumor 0 trials
-
Myeloid neoplasm 48 trials · 2,708 incl. sub-types
4 sub-types
- Myeloproliferative neoplasm 166 trials · 1,632 incl. sub-types Sub-types →
- Plasma cell myeloma 1,108 trials · 1,131 incl. sub-types Sub-types →
- Mast cell neoplasm 0 trials · 34 incl. sub-types Sub-types →
- CD4+/CD56+ hematodermic neoplasm 31 trials
-
Leukemia 361 trials · 2,566 incl. sub-types
12 sub-types
- Acute leukemia 124 trials · 2,246 incl. sub-types Sub-types →
- Lymphoid leukemia 24 trials · 1,362 incl. sub-types Sub-types →
- Myeloid leukemia 30 trials · 1,334 incl. sub-types Sub-types →
- Chronic leukemia 15 trials · 748 incl. sub-types Sub-types →
- Childhood leukemia 23 trials · 172 incl. sub-types Sub-types →
- Monocytic leukemia 4 trials · 22 incl. sub-types Sub-types →
- Mast cell leukemia 9 trials
- Central nervous system leukemia 4 trials
- Testicular leukemia 2 trials
- Aleukemic leukemia 0 trials Sub-types →
- Chronic erythremia 0 trials
- Splenic manifestation of leukemia 0 trials Sub-types →
-
Refractory hematologic cancer 62 trials · 310 incl. sub-types
6 sub-types
- Refractory plasma cell neoplasm 228 trials
- Refractory precursor T-lymphoblastic lymphoma/leukemia 31 trials
- Refractory hairy cell leukemia 9 trials
- Refractory anemia with excess blasts in transformation 6 trials
- Myelodysplastic syndrome with multilineage dysplasia 0 trials Sub-types →
- Refractory cytopenia of childhood 0 trials
-
Central nervous system hematopoietic neoplasm 0 trials · 107 incl. sub-types
4 sub-types
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Central nervous system leukemia 4 trials
- Intracranial cavernous angioma 0 trials
- Pituitary gland basophil adenoma 0 trials
-
Histiocytic and dendritic cell neoplasm 10 trials · 99 incl. sub-types
3 sub-types
- Dendritic cell tumor 0 trials · 92 incl. sub-types Sub-types →
- Histiocytic sarcoma 9 trials
- Indeterminate dendritic cell tumor 1 trial
-
Myelodysplastic syndrome with excess blasts 72 trials · 84 incl. sub-types
2 sub-types
-
Myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2 0 trials · 4 incl. sub-types
Most studied deeper sub-types
-
Can a lung drug stop transplant rejection? new trial tests Alpha-1 antitrypsin for GVHD
Disease control Stopped earlyThis study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…
Phase 2/3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a daily pill shrink the spleen in myelofibrosis?
Disease control Stopped earlyThis phase 3 trial is testing an experimental oral drug, SAR302503, in people with a rare bone marrow disorder called myelofibrosis who have an enlarged spleen. Participants are randomly assigned to receive one of two doses of the drug or a placebo. The main goal is to see if the…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Engineered immune cells take on viruses in cancer patients
Disease control Stopped earlyThis early-stage trial is testing whether genetically modified T-cells can safely control viral infections in cancer patients with weakened immune systems. The T-cells are designed to target specific viruses like CMV, BK virus, or COVID-19. The study involves 30 participants and …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental lung inflammation treatment trial shuts down after just one patient
Disease control Stopped earlyThis phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for myelofibrosis patients who stop responding to standard therapy
Disease control Stopped earlyThis phase 2 trial tests an experimental drug called SAR302503 in people with myelofibrosis who have already been treated with ruxolitinib. The main goal is to see if the drug can shrink the spleen by at least 35% after six months of daily oral capsules. The study also tracks whe…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo targets brain metastases in advanced cancers
Disease control Stopped earlyThis study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Rapid test plus targeted antibiotic shows promise for tough infections in blood cancer patients
Disease control Stopped earlyThis study tested whether the antibiotic ceftolozane-tazobactam, guided by a rapid molecular test, could effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. The 17 participants received the antibiotic t…
Phase 4 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can extra care after transplant help older patients live better?
Disease control Stopped earlyThis study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…
Phase 2/3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Cancer Patients' COVID-19 trial halted after just 4 volunteers
Disease control Stopped earlyThis early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …
Phase 1/2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug BR108 tested in blood cancer patients – early results uncertain
Disease control Stopped earlyThis early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check sa…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Promising combo for tough leukemia hits roadblock: trial stopped early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and se…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…
Phase 1/2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Cancer drug trial halted early – what happened?
Disease control Stopped earlyThis phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for kids after transplant: study tests safer GVHD prevention
Disease control Stopped earlyThis study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs after day 60 could lower the risk of severe GVHD. Only 3 children too…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Radiation after failed CAR t: tiny study halted early
Disease control Stopped earlyThis pilot study looked at whether radiation therapy could help people with lymphoma that did not respond to CAR T cell therapy. Only 3 participants were enrolled before the study was terminated. The main goal was to check safety and side effects of adding radiation shortly after…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a PET scan spot silent heart danger from cancer drugs?
Diagnosis Stopped earlyThis pilot study tested whether a special PET scan (FDG-PET/CT) can detect hidden heart inflammation in cancer patients receiving immune checkpoint inhibitors (ICIs). The goal was to catch this inflammation early, before it becomes severe. Only 2 participants were enrolled, and t…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Can a smartphone app help cancer patients fight depression?
Symptom relief Stopped earlyThis study tested whether a digital platform could improve collaborative care for depression in cancer patients. About 300 adults receiving cancer treatment with significant depression symptoms were enrolled. The platform aimed to help care managers track symptoms and coordinate …
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Taste and smell training offers hope for chemo patients
Symptom relief Stopped earlyThis study tested a sensory rehabilitation program for people who lost their sense of smell or taste after chemotherapy for blood cancers like multiple myeloma or lymphoma. The program involved exercises to retrain the nose and tongue. Only 5 people enrolled before the study ende…
Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
New platform seeks to break down barriers for underserved cancer patients in clinical trials
Knowledge-focused Stopped earlyThis study looked at why minority cancer patients often don't take part in clinical trials. Researchers surveyed patients about their understanding and attitudes, then tested an educational video and booklet to see if it boosted enrollment. The goal was to create a personalized p…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Siblings' voices: what kids want to know when a brother or sister has cancer
Knowledge-focused Stopped earlyThis study looked at how healthy brothers and sisters of children with blood cancer felt about the information they got about the disease. Researchers interviewed 7 children aged 6 to 12 to understand their satisfaction and what they thought about the illness. The goal was to imp…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC